Patents by Inventor Adrian Wiestner

Adrian Wiestner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
    Publication number: 20230029635
    Abstract: Disclosed are anti-C3d antibodies or fragments thereof. Also disclosed are methods of killing cancer cells, methods of preparing anti-C3d antibodies, and pharmaceutical compositions.
    Type: Application
    Filed: December 8, 2020
    Publication date: February 2, 2023
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, The Scripps Research Institute
    Inventors: Adrian Wiestner, Christoph Rader, Haiyong Peng, Sivasubramanian Baskar, Erika Gaglione
  • ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)
    Patent number: 8748114
    Abstract: It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA or protein.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: June 10, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Louis M. Staudt, Andreas Rosenwald, Wyndham Wilson, Todd S. Barry, Adrian Wiestner
  • Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
    Patent number: 8637560
    Abstract: The present invention features imidazolidinone compounds and pharmaceutical compositions of imidazolidinone compounds. The compounds of the invention are utilized in methods of treating a deubiquitination-related disorder in a subject and inhibiting p97-associated deubiquitination.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: January 28, 2014
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: William Trenkle, Adrian Wiestner, Qiuyan Wang, Yihong Ye, Helena Mora-Jensen
  • Hydrazone and diacyl hydrazine compounds and methods of use
    Patent number: 8518968
    Abstract: Disclosed herein are novel hydrazone and diacyl hydrazine derivatives that are inhibitors of the endoplasmic reticulum-associated protein degradation (ERAD) pathway. Also disclosed are hydrazone and diacyl hydrazine derivatives as potent and selective inhibitors of the p97 ATPase. These agents provide useful tools for the study of protein degradation and other processes involving p97. Methods of treating diseases or disorders for which p97 inhibition and/or ER stress induction is an effective treatment with certain hydrazone and diacyl hydrazine derivatives are also disclosed.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: August 27, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian Wiestner, Yihong Ye, Qiuyan Wang, William C. Trenkle, Bidhan A. Shinkre
  • HYDRAZONE AND DIACYL HYDRAZINE COMPOUNDS AND METHODS OF USE
    Publication number: 20120316198
    Abstract: Disclosed herein are novel hydrazone and diacyl hydrazine derivatives that are inhibitors of the endoplasmic reticulum-associated protein degradation (ERAD) pathway. Also disclosed are hydrazone and diacyl hydrazine derivatives as potent and selective inhibitors of the p97 ATPase. These agents provide useful tools for the study of protein degradation and other processes involving p97. Methods of treating diseases or disorders for which p97 inhibition and/or ER stress induction is an effective treatment with certain hydrazone and diacyl hydrazine derivatives are also disclosed.
    Type: Application
    Filed: December 3, 2010
    Publication date: December 13, 2012
    Applicant: The United States of American, as Represented by the Secretary, Dept. of Health and Human Services
    Inventors: Adrian Wiestner, Yihong Ye, Qiuyan Wang, William C. Trenkle, Bidhan A. Shinkre
  • ZAP-70 EXPRESSION AS A MARKER FOR CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
    Publication number: 20110236915
    Abstract: It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA mRNA or protein.
    Type: Application
    Filed: June 7, 2011
    Publication date: September 29, 2011
    Inventors: Louis M. Staudt, Andreas Rosenwald, Wyndham Wilson, Todd S. Barry, Adrian Wiestner
  • ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)
    Patent number: 7981610
    Abstract: It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA or protein.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: July 19, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Louis M. Staudt, Andreas Rosenwald, Wyndham Wilson, Todd S. Barry, Adrian Wiestner
  • IMIDAZOLIDINONE COMPOUNDS, METHODS TO INHIBIT DEUBIQUITINATION AND METHODS OF TREATMENT
    Publication number: 20100286091
    Abstract: The present invention features imidazolidinone compounds and pharmaceutical compositions of imidazolidinone compounds. The compounds of the invention are utilized in methods of treating a deubiquitination-related disorder in a subject and inhibiting p97-associated deubiquitination.
    Type: Application
    Filed: July 18, 2008
    Publication date: November 11, 2010
    Inventors: Adrian Wiestner, William Trenkle, Qiuyan Wang, Yihong Ye, Helena Mora-Jensen
  • ZAP-70 EXPRESSION AS A MARKER FOR CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
    Publication number: 20080227741
    Abstract: It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA or protein.
    Type: Application
    Filed: December 12, 2007
    Publication date: September 18, 2008
    Inventors: Louis M. Staudt, Andreas Rosenwald, Wyndham Wilson, Todd S. Barry, Adrian Wiestner
  • ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Patent number: 7329502
    Abstract: It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA mRNA or protein.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: February 12, 2008
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Louis M. Staudt, Andreas Rosenwald, Wyndham Wilson, Todd S. Barry, Adrian Wiestner
  • ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Publication number: 20030203416
    Abstract: It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA mRNA or protein.
    Type: Application
    Filed: December 3, 2002
    Publication date: October 30, 2003
    Applicant: The Govt. of the USA as represented by Secretary of the Dept. of Health and Human Services
    Inventors: Louis M. Staudt, Andreas Rosenwald, Wyndham Wilson, Todd S. Barry, Adrian Wiestner